Istaroxime information

Istaroxime
Clinical data
Other names	(3Z,5α)-3-[(2-Aminoethoxy)imino]androstane-6,17-dione
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (3E,5S,8R,9S,10R,13S,14S)-3-(2-aminoethoxyimino)-10,13-dimethyl-1,2,4,5,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-6,17-dione;
PubChem CID	9841834;
ChemSpider	28521583;
ChEMBL	ChEMBL2093999;
CompTox Dashboard (EPA)	DTXSID20870222 ;
Chemical and physical data
Formula	C21H32N2O3
Molar mass	360.498 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CCC(=NOCCN)C[C@@H]1C(=O)C[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C;
	InChI InChI=1S/C21H32N2O3/c1-20-7-5-13(23-26-10-9-22)11-17(20)18(24)12-14-15-3-4-19(25)21(15,2)8-6-16(14)20/h14-17H,3-12,22H2,1-2H3/t14-,15-,16-,17+,20+,21-/m0/s1; Key:MPYLDWFDPHRTEG-IFVNMTGRSA-N;

Istaroxime is an investigational drug under development for treatment of acute decompensated heart failure

Originally patented and developed by Sigma-Tau, it was sold to CVie Therapeutics in July 2012.^[1]

^ Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. (June 2009). "Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial". American Heart Journal. 157 (6): 1035–41. doi:10.1016/j.ahj.2009.03.007. PMID 19464414.

and 4 Related for: Istaroxime information